Viking opens oral VK2735 Phase 3 SUNRISE as $960m cash backs two late-stage tracks

What happened

Viking Therapeutics has started its Phase 3 SUNRISE programme for oral VK2735, according to an investor release filed with the US Securities and Exchange Commission on 28 October 2026. The programme covers two indications: obesity and type 2 diabetes. In the same update, the company reported $960m in cash.

The release also says the subcutaneous VK2735 VANQUISH studies remain on track to complete in 2027. Viking therefore now has two late-stage tracks for the same molecule, one injectable and one oral, running in parallel.

The record does not give the number of SUNRISE trials, enrolment targets, endpoints, dose levels, comparators, countries or sites. It also gives no readout timelines for the oral programme. Anything beyond the existence of the programme, its two indications and the VANQUISH completion guidance is not yet known from the information available.

Why it matters for trial operations

A sponsor running two Phase 3 programmes at once creates operational load that is familiar to clinical operations teams. Both programmes draw on the same pool of investigator sites, the same patient populations and the same vendor ecosystem. Obesity and type 2 diabetes are areas where many sponsors compete for sites and participants. How Viking staggers site selection and recruitment across SUNRISE and VANQUISH is not described in the record.

The cash figure matters mainly as context. A reported $960m balance indicates the company has resources alongside two late-stage efforts. The record does not say how much is allocated to each programme, and this article does not draw conclusions about financing, valuation or outcomes.

The 2027 completion guidance for VANQUISH is a sponsor expectation, not a result. The record contains no efficacy or safety data for either the oral or the subcutaneous formulation, so no comparison between them can be made.

Regulatory context: computerised systems in the spotlight

On the same day, EMA published a notice to sponsors on the validation and qualification of computerised systems used in clinical trials. The details are not set out in the information available, so we cannot say what it requires or how it changes earlier expectations. The document's file name suggests it is a revised version, but the record does not describe what changed.

The notice is relevant to any large, multi-site programme. In general terms, sponsors are expected to be able to show that the electronic systems that capture, process and store trial data are fit for purpose and controlled. Typical examples are electronic data capture, randomisation and trial supply systems, and electronic patient-reported outcome tools. Programmes with many sites and several vendors have more systems and interfaces to demonstrate control over.

The notice has no stated link to Viking. It is relevant here only because sponsors starting multi-trial Phase 3 programmes are the ones setting up these systems now. Teams should read the full EMA document before concluding what it means for their own validation documentation.

Who is affected, and a read-across from Alzheimer's

The most direct audience is sponsors and CROs working in metabolic disease, where competition for sites and participants is part of the planning picture. Site networks and data-management vendors are also affected, since a programme of this kind adds to their workload.

A second item from the same week shows how safety monitoring shapes trial design in other fields. On 26 October, Acumen Pharmaceuticals said it expects topline results next month from its 542-patient Phase 2 ALTITUDE-AD trial of sabirnetug in early Alzheimer's disease. Among the safety measures is the rate of ARIA (amyloid-related imaging abnormalities), a class-relevant imaging finding in this area. The record gives no results.

The comparison is limited. Acumen's trial is Phase 2 and Viking's programme is Phase 3, in different diseases. What they share is that late-stage trial planning has to define upfront which safety signals are monitored and how. For Viking's programmes, the record does not specify safety monitoring.

What to watch

For SUNRISE, the first items to look for are the registry entries and protocol details: size, duration, endpoints and geography. Those will show how the programme compares with the subcutaneous studies and whether EU sites are involved, which would bring EU-specific expectations into play.

For VANQUISH, watch for any change to the 2027 completion guidance in later company updates. For Acumen, the November topline release will show how ARIA is reported alongside efficacy. For EMA, the full notice on computerised systems is the key document for validation and qualification practice.